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Abstract
Attention Deficit Hyperactivity Disorder (ADHD) is associated with considerable burden of illness at a patient, family
and societal level. Although pharmacological treatment is recommended by authoritative guidelines, evidence on
its influence on the broader burden of illness is limited. As treatment induces costs, proper healthcare decision
making requires evidence on the associated societal costs or benefits and particularly the difference that response
to treatment can make.
Data on ADHD related resource use of patients 8–18 years and parents were collected by means of a cross-sectional,
online survey amongst members of the Dutch parent association. Children were stratified to responders and
non-responders to treatment according to pre-defined expert definitions.
Analyses were performed on 618 questionnaires (428 responders; 190 non-responders to treatment). Children were
11.8 years on average and mainly boys (82 %). Total monthly costs for children were €578 and €839 for responders and
non-responders, respectively (p = 0.021), with a breakdown to direct medical costs (€322 vs. €512; p = 0.068), direct
non-medical costs (€222 vs. €296; p = 0.090), and indirect non-medical costs (€34 vs. €57; p < 0.001). For parents, total
costs were €246 vs. €399 for the responding and non-responding children, respectively (p = 0.006), with a breakdown
to direct medical costs (€130 vs. €211; p = 0.010) and indirect non-medical costs (€116 vs. €181; p = 0.092). Total
monthly costs of children and their parents together were €824 and €1228 for responders and non-responders to
treatment, respectively (p = 0.002).
These results stress the importance of a focus on response to treatment, not only beneficial for patients and their
family, but also resulting in considerable societal benefits.
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Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is a
heterogeneous psychiatric disorder characterized by a
chronic pattern of age-inappropriate inattention, hyper-
activity and impulsivity with a worldwide-pooled preva-
lence of 5.3 % (Asherson 2004; Polanczyk et al. 2007;
Swanson et al. 2009). Adverse consequences of ADHD
may be far-reaching and symptoms often persist into
adulthood (Barkley 2008; Coghill et al. 2008; Faraone et al.
2006; Michielsen et al. 2012).
ADHD is associated with a considerable burden of
illness at both the patient, family, and societal level
(Birnbaum et al. 2005; Doshi et al. 2012; Erskine et al.
2014; Le et al. 2013). Several studies concluded that
ADHD has a negative impact on family, school and en-
vironmental level reflected in a lower quality of life (QoL),
increased use of healthcare resources and risk for injur-
ies, substance abuse, delinquency, and driving violations
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(Danckaerts et al. 2009; De Ridder & De Graeve 2006;
Hakkaart-van Roijen et al. 2007; Mannuzza et al. 2008;
Thompson et al. 2007; van den Ban et al. 2014; van der
Kolk et al. 2014). The influence of ADHD on others than
the patient is previously shown by productivity losses of
parents and an increased use of healthcare resources by
family members (Birnbaum et al. 2005; Swensen et al.
2003). Treatment by medication has been shown to de-
crease ADHD symptoms and to consequently improve the
level of functioning. Medication is recommended by au-
thoritative treatment guidelines worldwide as a first-line
treatment option in case of ADHD (Banaschewski et al.
2006; Canadian Attention Deficit Hyperactivity Disorder
Resource Alliance 2010; National Institute for Health and
Clinical Excellence 2006; Trimbos-instituut et al. 2005;
Wolraich et al. 2011). A recent systematic review of long-
term outcomes of ADHD treatment and non-treatment
supports the premise that without accurate treatment,
people with ADHD experience poorer long-term outcomes
(Shaw et al. 2012). Also, non-adherence to treatment could
jeopardize treatment outcome (van den Ban et al. 2010).
However, evidence is limited regarding the influence of
treatment by medication on health care resource use of
ADHD patients and their families, and the associated
economic burden. This is a hindrance for the evaluation
of the cost-effectiveness of current and future pharmaco-
logical interventions for ADHD (Le et al. 2013).
Studies on health care resource use and costs are prefer-
ably conducted from the societal point of view (Jonsson
2009). A profound societal analysis includes medical (inside
the health care sector) and non-medical costs (outside the
health care sector), both direct (e.g. a visit to a doctor)
and indirect costs (e.g. absence from work due to illness)
(Jonsson 2009). This broad societal perspective is especially
indicated in evaluating the economic burden of chronic
diseases like Alzheimer’s disease, Multiple Sclerosis,
Rheumatoid Arthritis and ADHD. These are all exam-
ples of disease areas where new innovations could lead
to reductions in costs for society due to reductions in
productivity gains and reductions in costs for commu-
nity and informal care (Jonsson 2009). However, only
few studies have monetized the impact of ADHD sys-
tematically by providing an impression of the overall
impact of ADHD from a societal perspective with a
comprehensive measurement of indirect costs (Doshi et al.
2012; Le et al. 2013). A recent review concluded that data
is lacking to draw conclusions regarding the relative
cost-effectiveness of different pharmacological agents in
ADHD (Le et al. 2013). In recent years, the issue of
non-compliance with (pharmacological) treatment is stud-
ied further to evaluate the clinical and economic effects of
the management of compliance in patients (Hiligsmann
et al. 2012). In ADHD treatment, persistence to treatment
is frequently suboptimal indicating impaired compliance
(van den Ban et al. 2010). Poor compliance, or in broader
terms poor response to treatment, reduces the potential
benefits from therapy. To our knowledge, costs in children
with ADHD have not been studied in association to re-
sponse to treatment.
This paper therefore presents a cost study on ADHD
from the societal perspective including costs related to
resource use and productivity losses. As medication is
recommended by guidelines as a first-line treatment op-
tion and response to treatment is associated with poten-
tial treatment benefit, proper healthcare decision making
requires evidence on the associated societal costs or bene-
fits and particularly the difference response to treatment
can make.
Methodology
The present study was part of a larger study on the bur-
den of ADHD from a societal perspective including QoL
(van der Kolk et al. 2014). The current study analyses all
direct and non-medical indirect costs related to ADHD
(Table 1). Data on healthcare consumption of children
and their parents and productivity losses of parents were
collected by means of a cross-sectional, online survey that
was completed by parents.
Study sample
The study sample was derived out of the members of the
Dutch association Balans for parents of children with de-
velopmental disorders (amongst others, but not limited to
Table 1 Types of resource use included for children (Cha) and
parents (Pb) or both groups (Ch-P)
Direct Indirect
Medical Medical consultations (Ch-P)c d
Skills training (Ch)
Parent training (P)
Day-care treatment (Ch)
Hospitalization (Ch)
Medication (Ch-P)
Non-medical Remedial teaching at
school (Ch)
Agency for child
welfare (Ch)
Weekend care (Ch) Police (Ch)
Care after school (Ch) Special education (Ch)
Diet (Ch) Productivity losses
Absenteeism (P)
Presenteeism (P)
aCh: Item included in the cost calculation of the children only
bP: Item included in the costs for parents referred to their own health
consumption because of their child’s ADHD
cCh&P: Item included in both the cost calculation for the children as well as in
the cost calculation for the parents, but costs for children are not included in
the costs for parents
dIndirect medical costs are excluded according to the Dutch guidelines for
pharma-economic research (College voor zorgverzekeringen afdeling
pakket 2006)
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ADHD, Asperger’s syndrome, Dyslexia, oppositional defi-
ant disorder (ODD), and conduct disorder (CD)). Parents
of children with ADHD were asked via the magazine of
the association to join the study online by means of a per-
sonal login code. Inclusion criterion: being a parent of a
child aged 8–18 years diagnosed with ADHD. Because of
this membership, it was assumed valid to rely on the par-
ents’ knowledge about the ADHD diagnosis of their child.
Due to anonymity it was not possible to verify whether
the diagnosis was indeed valid.
The questionnaire was available from 01-09-2010 until
03-10-2010. The parent taking care of the child most of
the day was asked to complete the questionnaire. Parents
were not reimbursed for their participation in any way. In
case the parent had more than one child with ADHD, par-
ents were asked to answer the questions for their youngest
child. Since the study did not interfere with clinical prac-
tice, according to Dutch regulation no approval of an eth-
ics committee was needed. Also, with the methodology of
this study focusing on parents instead of patients, it was
not obligatory to use informed consent forms. Neverthe-
less, the protocol took into account all privacy aspects and
all necessary efforts were taken in this study to protect
privacy. Participants were informed on the purpose of data
collection (scientific publication), respondents were fully
free to decide to join and were able to exit the question-
naire at any time. Due to the login code that was distrib-
uted by Balans magazine, only members of Balans were
able to access the questionnaire. The questionnaire could
be completed only once per IP address, but these IP ad-
dresses were not saved and/or traceable so participants’
anonymity was guaranteed. Also, adequate security mea-
sures were employed in order to prevent unauthorized ac-
cess, manipulation to or disclosure of the personal data
although these were already unidentifiable when stored.
Responder groups
In order to investigate the association between costs and
response to treatment, descriptions for response to treat-
ment had to be defined since these were not readily
available. These descriptions were created by five Dutch
ADHD experts. This number of five experts was consid-
ered appropriate for the study, in accordance with mini-
mum requirements of a Delphi panel (Evans & Crawford
2000). The panel of experts was selected based on their
experience in the field of ADHD treatment, and a scien-
tific focus. The experts included were child-and youth
psychiatrists (n = 5), both male (n = 4) and female (n = 1)
and aged 43 to 55 (mean 49.8). The experts had 10 to
22 years of experience with ADHD medication and
treated 30–90 ADHD patients per month. The experts
were consulted independently and were not aware of
the identity of the other experts joining the panel. An
expert not joining the Delphi panel verified the questions
proposed to the experts in advance. The questions for the
panel were sent and returned by email. After all experts
had returned the questionnaires, their answers were com-
bined. The proposals for the final answers, as well as the
anonymous individual answers of the participants were re-
ported to the experts after round 1. In the second round,
experts were asked whether they liked to change their pre-
vious answers, based on the proposal for the final answer.
Before distributing the questions to the experts, it was de-
cided that consensus was supposed to be reached after
two rounds of answers when (a) feedback of the experts
was clear and (b) when experts did not all change their an-
swers based on the mean of the feedback of the first
round. The experts indicated that two assumptions were
crucial for the foundation of the definitions for response
to treatment and non-response to treatment. First, based
on an earlier study, response to medication had to be de-
fined by recovery both at home and at school in order to
reflect a proper description of the child’s daily functioning
(functioning - F) (Buitelaar et al. 1995; Hodgkins et al.
2013). Second, as compliance to medication is known to
play an important role in the child’s functioning, it was
considered necessary to include a statement on the child’s
compliance as well (compliance - C) (Charach & Fernandez
2013). Theoretically, this led to the following combinations:
 (C+; F+): Compliance to prescribed daily dose of
medication, no problems in functioning.
 (C−; F−): Non-compliance to prescribed daily dose of
medication, problems in functioning.
 (C−; F+): Non-compliance to prescribed daily dose of
medication, no problems in functioning.
 (C+; F−): Compliance to prescribed daily dose of
medication, problems in functioning.
The experts decided to exclude combinations (C−; F+)
and (C+; F−). Experts considered (C−; F+) to describe
children not requiring medication, as no problems arise
when medication is not taken according to prescription.
(C+; F−) was considered to reflect several situations in
which proper compliance is not translated into proper
functioning: inappropriate dosing, inappropriate medica-
tion, or presence of an undiagnosed but relevant comor-
bid condition. The design of the study precluded to analyze
these situations. The two remaining combinations, (C+; F+)
and (C−; F−), were the basis for responder group definition.
As it was deemed necessary to provide parents with a
hands-on description of these groups, the experts oper-
ationalized the combinations to the following descrip-
tions based on treatment compliance and functioning
in family, school and the environmental level:
 Responder to treatment: ‘Your child uses the
prescribed daily dose of medication. Using this
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treatment, your child’s functioning is fine and there
are no noteworthy problems at home, at school, with
peers or during leisure time’.
 Non-responder to treatment: ‘The daily dose of
medication used by your child differs from the dose
prescribed. Using this treatment, your child’s
functioning is quite fine, but he/she is hampered by
problems at home, at school, with peers or during
leisure time for short periods of time’.
The questionnaire
The questionnaire on healthcare consumption and
productivity losses for patients with psychiatric disor-
ders (TiC-P) was used, which is designed for self-report
and is focused on psychiatric disorders like ADHD (van
Roijen et al. 1996). Two versions are available, one for
adults and one for adults to describe their children
(Bouwmans et al. 2013b; Bouwmans & Hakkaart-van
Roijen 2013b). The selection of this questionnaire was
based on feasibility, reliability and validity combined with
comprehensiveness of cost items and ability of online use
(Bouwmans et al. 2013a). The questionnaire had been
used on an ADHD sample in another study before (Hak-
kaart-van Roijen et al. 2007). In the present study, both
TiC-P versions were used. The questionnaire was adjusted
using information from a previously performed study
focused on societal cost related to ADHD as is allowed
by the TiC-P manual (Bouwmans & Hakkaart-van Roijen
2013a; Hakkaart-van Roijen et al. 2007). The recall period
was one month for both medical consumption and prod-
uctivity losses. TiC-P starts with general demographic
questions on gender, age, (type of ) education, marital
status, and job.
TiC-P questionnaires are generic, meaning that items
are not related to a specific disorder. In this study, re-
source use was supposed to be related to the ‘target dis-
order’ ADHD. Parents were provided with examples of
costs that were either related (visiting a doctor for ADHD
problems) or non-related to ADHD (visiting an ear, nose
and throat specialist for ear tubes) to aid them in making
a correct distinction. This could also mean costs for par-
ents getting coaching and/or parenting tips; this is only
necessary because of their child with ADHD and therefore
these costs are considered related to ADHD. Costs for
parents referred to their own health consumption only
plus costs due to productivity losses.
Table 1 presents the cost items that were included,
Table 2 presents the unit costs per cost item. For chil-
dren, additional questions to Table 2 were focused on
costs for diet, the use of ADHD medication, use of spe-
cial education and absence from school or sports. Costs
of productivity losses were focused on productivity losses
of paid work including absenteeism (absence from work)
and presenteeism (reduced productivity while at work).
Non-paid work was not included in this study, since par-
ents of children aged 8–18 were expected to have limited
voluntary activities.
Cost calculation
Bottom-up methodology was used to calculate total dir-
ect medical costs; that is, the total number of medical
contacts was multiplied by the reference prices based on
the Dutch manual for cost studies (prices were updated
to 2012 prices) (Hakkaart-van Roijen et al. 2011). A visit
to ‘RIAGG’ (Dutch mental health facility: a combination
of 1st and 2nd line care) was assumed to have similar
costs as 1st line mental health care in case of ADHD.
Unit costs for a visit to a school doctor and a company
doctor were assumed to be similar to a general practi-
tioner visit as costs for a school doctor and a company
doctor were not defined in the costing manual. These
assumptions were confirmed by a specialist in costing
studies (LH). Costs for individual and group trainings
were not specified in the costing manual. For individual
sessions, costs for ambulatory 2nd line care were assigned
based on communication by the Dutch mental health as-
sociation ‘GGZ Nederland’. For group trainings, the asso-
ciation estimated time used by the expert divided by the
number of clients per session. For day-care, a weighted
average of day-care treatment (8 h a day) and half-time
treatment (4 h a day) was used (day-treatment €183.70 +
half-time treatment €163.53). For parents, the average
number of days of medication use in the entire group of
parents per month was multiplied by mean public Dutch
costs of medication use in adults (€0.66 per day) (Stichting
Farmaceutische Kengetallen 2012). Direct non-medical
costs related to weekend care and care after school were
based on several sources as these were not defined in the
costing manual. Weekend care was estimated based on
productivity costs (Hakkaart-van Roijen et al. 2011). For
remedial teaching, average price per hour for remedial
teaching were used for cost calculation (Landelijke ber-
oepsvereniging remedial teachers 2014). Care after school
was rated based on average costs for baby-sitting (Nibud
2013). For diets, parents were asked to define costs
below €25, between €25 and €50 or above €50 in one
month if a special diet was indicated. For indirect non-
medical costs, the agency for child welfare and police were
assumed to have the same cost price since costs for police
was not defined in the costing manual (Hakkaart-van
Roijen et al. 2011). Prices for special education were based
on prices of the Dutch Ministry of Education with a yearly
additional cost of €4700 (Ministerie van Onderwijs 2012).
This led to extra monthly costs for special primary and
special secondary education of €392 compared to regu-
lar education. For the questions on child’s health-related
school absence and failure to participate in sports due to
ADHD no costs were assigned. Cost of absence from work
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of the parent related to their child with ADHD was calcu-
lated by multiplying the number of days off work with
predefined productivity costs per hour of absence with a
specification to age group and gender (Hakkaart-van Roi-
jen et al. 2011). Costs of presenteeism was determined by
the Osterhaus method (Osterhaus et al. 1992). Parents
were asked about the number of days of hindrance due to
ADHD of their child and their estimated efficiency on
these days in comparison to usual efficiency. Linear ex-
trapolation (LE) was applied as it was in a former ADHD
study as well (Hakkaart-van Roijen et al. 2007). Applying
LE, all costs were extrapolated to one year by multiplying
the monthly costs by twelve assuming the monthly costs
to reflect usual costs. There is no specific reason to as-
sume that the cost distribution is non-linear, although
there might be small variations during the year.
Statistical analysis
Completeness of the data is reported based on numbers
completing the questionnaire. Furthermore, the data was
reviewed for fraudulent responses, errors (intentional or
not), missing data and possible strange patterns indicating
programming errors. Study variables are described using
absolute numbers (mean and median), percentages and
95 % confidence intervals. Missing data was replaced by
means of multiple imputation as is the recommended
Table 2 Unit costs used for children (Ch) and parents (P) or both groups (Ch-P) in Euro 2012
Ch-P Unit costs (Hakkaart-van Roijen et al. 2011)a
Consultation per session - -
General Practitioner Ch-P 29.73
Psychologistb Ch-P 84.95
Social worker Ch-P 69.02
Psychotherapist, first linec Ch-P 81.76
RIAGGd Ch-P 81.76
Phychiatrist outpatients’ department P 109.37
Medical specialist Ch 109.37
Emergency Room Ch 160.34
Physiotherapist Ch 38.23
Occupational therapist Ch 23.36
Speech therapist Ch 35.04
Alternative therapist Ch-P 50.00 (Nederlandse Orde van Alternatieve Genezers 2013)
Paramedical (physiotherapist, occupational and alternative therapist) P 37.12
School doctor Ch 29.73
Company doctor P 29.73
Trainings per session - -
Social skills training/creative therapy/self regulatione - individual Ch 181.58
Social skills training/creative therapy/self regulatione - group Ch 100.00
Psychological educationf/parent training/family coach - individual P 181.58
Psychological educationf/parent training/family coach - group P 100.00
Day-care treatment Ch 173.62
Hospitalization Ch 246.35
Agency for child welfare Ch 69.02
Weekend care (hours) Ch 13.27
Police (contacts) Ch 69.02
Remedial teaching at school (hours)g Ch 55.00 (Landelijke beroepsvereniging remedial teachers 2014)
Care after-school (hours) Ch 5.93 (Nibud 2013)
aDutch cost manual unless specified otherwise and prices were indexed to 2012 prices
bSecond line care aimed at more severe complaints needing a longer treatment duration
cShort duration (up to 8 sessions) aimed at mild to moderate complaints
dRegional institution for ambulant psychiatric health care
eTo control or direct oneself according to rule
fProvide information to parents regarding coping with the ADHD of their child
gSpecial teaching for backward and slow learners
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method to reflect estimates across the range of circum-
stances considered (Manca & Palmer 2005). Variables
were considered candidates for the imputation process
based on simple regression followed by a regression model
based on significance and their independent influence on
total costs. To check if distribution was normal, data were
tested for skewness. Descriptive statistics, independent
samples t-test and Chi-square test were used accord-
ingly for analyzing differences between groups (p < 0.05;
2-tailed). As healthcare cost data tend to be skewed,
tests were repeated using Mann–Whitney tests to check if
conclusions remained similar using a test for non-parametric
data. Multiple regression analysis was used to check for
independent influence of other factors than treatment
response on the mean total costs. A p-value of <0.05 was
considered significant. It was not possible to examine test-
retest reliability in this study, since the questionnaire was
administered only once. Analyses were performed in IBM
SPSS Statistics version 21.
Results
Demographic characteristics
Analyses were performed on 618 questionnaires of chil-
dren and 590 questionnaires of parents (28 respondents –
4.5 % – did not complete all questions). Table 3 reports on
the demographic characteristics for children and parents.
ADHD had mainly been diagnosed by a psychiatrists or a
pediatrician (67.8 and 17.8 %, respectively). Children were
reported to be a responder to treatment in 428 cases
(69.3 %) and non-responder to treatment in 190 cases
(30.7 %). Mean age of children was 11.8 years. The number
of comorbidities was similar between responder groups,
although there was a near-significant difference of more
children with three or more comorbidities in the non-
responder group compared to the responder group (p =
0.051). Comorbidities in the entire sample were Asthma
or chronic Bronchitis (n = 78; 13 %), Epilepsy (n = 7; 1 %),
Anxiety disorder (n = 80; 13 %), mood disorder (n = 66;
11 %), learning disorder (n = 235; 38 %), Gilles de la
Tourette/tic disorder (n = 25; 4 %), ODD/CD (n = 63;
10 %), mental retardation (n = 4; 0.6 %) and, Autism
Spectrum Disorder (ASD) (n = 152; 25 %). Anxiety disorder
(responder n = 48- 11.2 %, non-responder n = 32- 16.8 %;
p = 0.049), and mood disorder (responder n = 38 – 8.9 %,
non-responder n = 28 – 14.7 %; p = 0.023) differed signifi-
cantly between the responder and non-responder group
with more cases in the responder group.
Data on resource use for children was missing for 19
respondents and data on resource use and production
losses for parents for 27 respondents. This missing data
was replaced by means of multiple imputation. Data were
imputed based on the most optimal regression model. For
children, this model was based on responder group (re-
sponder vs. non-responder), gender of the parent, >1 child
with ADHD in the family and comorbidity. For parents,
data was imputed based on a model with responder
group, >1 child with ADHD, comorbidity and marital
status.
Table 4 presents the mean and median monthly costs
and their 95 % confidence interval for direct medical
and non-medical costs and indirect non-medical costs of
children and parents. The group non-responding chil-
dren incurred significantly higher total costs per month
compared to responding children. This was reflected in
total direct medical costs (€190 higher), direct non-medical
costs (€74 higher) and indirect non-medical costs (€23
higher). Day-care, trainings and doctor’s consultation
differed most remarkably between responder groups
(€71, €65 and €57 higher for non-responders, respectively),
with a significant difference for doctor’s consultations (1.3
visits responding children vs. 2 visits non-responding
children; p = 0.004). Remedial teaching at school accounted
for €33 extra per month for the non-responder group
(€132 for responders, €165 for non-responders; p = 0.045).
For the questions on child’s school absenteeism and failure
to participate in sports no costs were assigned. Absence
from sports due to ADHD was mentioned by the re-
sponder and the non-responder group (7.7 % vs. 16.8 %
respectively, p = 0.002). School absenteeism was reported
for 72 days by the responder group and for 50 days by
the non-responder group (16.8 % vs. 26.3 % respectively,
p = 0.003). Estimated annual costs for responders and non-
responders to treatment were €3864 vs. €6144 for direct
medical costs (p = 0.068), direct non-medical costs €2664
vs. €3552 (p = 0.090); indirect non-medical costs €408
vs. €684 (p < 0.001); and total costs for children €6936
vs. €10,068, p = 0.021 (responder vs. non-responder).
Monthly costs per responder group are reported in
Table 4.
For parents, total monthly costs were significantly differ-
ent between responder groups, incurring higher costs of
€153 for a parent when having a child non-responding to
treatment. Estimated annual costs were €2952 for the par-
ents of responding children and €4788 for parents of non-
responding children (p = 0.006). Both total direct medical
and indirect non-medical monthly costs were higher for
parents of a non-responding child with €81 (p = 0.010)
and €65 (p = 0.092) respectively. As for children, doctor’s
consultations differed largely between responder groups
and this difference was significant (responder 0.75 per
month vs. non-responder 1.43 per month; p = <0.001). Es-
timated annual costs were €1560 vs. €2532 for direct med-
ical costs (p = 0.010); indirect non-medical costs were
€1392 vs. €2172 (p = 0.092) and total costs were €2952 vs.
€4788 (p = 0.006) (responder vs. non-responder).
Costs for children and parents combined led to a sig-
nificant difference between responder groups in total
costs with €404 extra per month when a child is a non-
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responder to treatment (monthly costs responder €824,
non-responder €1228; p = 0.002). Estimated annual costs
were €9888 for the responder group and €14,736 for the
non-responder group (difference €4848; p = 0.002). Mul-
tiple regression showed that the factors treatment response,
gender of the parent, >1 child with ADHD and comorbidity
had an independent influence on total costs for children.
For total costs of parents, the factors treatment re-
sponse, >1 child with ADHD, comorbidity and marital
status of the parent were independent influencers.
Table 3 Children’s and parent’s characteristics
Entire sample Responder Non-responder p-value*
Children
N 618 (100.0 %) 428 (69.3 %) 190 (30.7 %)
Mean age 11.8 (8–18) 11.8 (8–18) 11.7 (8–18) 0.856
Gender
Male 509 (82.4 %) 359 (83.9 %) 150 (78.9 %) 0.138
Female 109 (17.6 %) 69 (16.1 %) 40 (21.1 %)
Number of comorbid disorders
0 166 (27.6 %) 126 (30.0 %) 40 (22.1 %) 0.051
1 242 (40.3 %) 170 (40.5 %) 72 (39.8 %)
2 132 (22.0 %) 89 (21.2 %) 43 (23.8 %)
3 or more 61 (10.1 %) 35 (8.3 %) 26 (14.4 %)
Type of education
Primary 241 (40.2 %) 165 (39.3 %) 76 (42.2 %) 0.119
Special primary 86 (14.3 %) 57 (13.6 %) 29 (16.1 %)
Secondary 219 (36.5 %) 165 (39.3 %) 54 (30.0 %)
Special secondary 54 (9.0 %) 33 (7.9 %) 21 (11.7 %)
Parents
N 590** (100.0 %) 415 (70.3 %) 175 (29.7 %)
Age (mean, range) 43.2 (30–63) 43.2 (30–63) 43.3 (30–59) 0.931
Gender
Male 28 (4.7 %) 22 (5.3 %) 6 (3.4 %) 0.328
Female 562 (95.3 %) 393 (94.7 %) 169 (96.6 %)
Marital status
Together 534 (90.5 %) 381 (91.8 %) 153 (87.4 %) 0.097
Alone 56 (9.5 %) 34 (8.2 %) 22 (12.6 %)
Education
Lower 83 (14.1 %) 59 (14.2 %) 24 (13.7 %) ***
Medium 265 (44.9 %) 182 (43.9 %) 83 (47.4 %)
Higher 232 (39.3 %) 166 (40.0 %) 66 (37.7 %)
Other 10 (1.7 %) 8 (1.9 %) 2 (1.1 %)
Paid job
Yes 471 (79.7 %) 328 (79.0 %) 143 (81.3 %) 0.541
No 120 (20.3 %) 87 (21.0 %) 33 (18.8 %)
More than 1 child with ADHD
Yes 133 (22.5 %) 85 (20.5 %) 48 (27.4 %) 0.065
No 457 (77.5 %) 330 (79.5 %) 127 (72.6 %)
*p value reflects differences between responders and non-responders
**28 parents did not complete the questionnaire
***Pearson Chi-Square not possible due to low expected numbers
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Discussion
The purpose of this study was to estimate ADHD related
costs for children and their parents taking a societal
perspective associated with treatment response. Non-
response to treatment was shown to be associated with
significant higher direct and indirect costs both inside
and outside healthcare for children as well as their par-
ents. Estimated annual costs differed between response
groups, with extra costs of €4848 for non-responders.
Costs for special education were very low relative to
the other cost items in this study. This could reflect lit-
tle need for extra attention, but it can also be a reflec-
tion of the general national Dutch trend towards less
use of special education (Dekker 2015). A study on the
economic impact of ADHD in Europe concluded that
the largest cost category was in fact in education repre-
senting 50 % of national costs on average (Le et al.
2013). The study did not include non-paid work based
on the assumption that parents of children aged 8–18
would have limited voluntary activities. They could
be coach of sports teams, be of help in their church or
follow higher education. These costs were not included
and could have impacted the absolute results. Most
children were boys, which is consistent with other stud-
ies in ADHD. In the entire sample, only 28 % had no
comorbidity and 10 % even had more than three
Table 4 Mean (median; 95 % CI) costs of children with ADHD and parents per month (in Euro 2012)
Entire sample Responder Non-responder p-value*
Children
Direct Medical costs
Doctor’s consultations** 114 (30) 96 (0; 78 – 115) 153 (95; 123 – 193) 0.004
Trainings 126 106 (0; 69–148) 171 (0; 117 – 240) 0.068
Day-care treatment 73 51 (0; 11–84) 122 (0; 32 – 218) 0.144
Hospitalization 41 41 (0; −10 – 93) 41 (0; −37 – 125) 0.999
Medication 26 (12) 27 (12; 25–30) 24 (12; 20 – 29) 0.300
Diet 5 4 (0; 2 – 5) 6 (0; 4 – 10) 0.145
Total direct medical costs 386 (109) 326 (96; 222–422) 518 (145; 334–691) 0.068
Direct non-medical costs
Weekend care 83 80 (0; 59 – 104) 91 (0; 60 – 122) 0.578
Remedial teaching at school 142 (110) 132 (0; 114 – 151) 165 (110; 137–194) 0.045
Care after-school 6 6 (0; 3 – 9) 7 (0; 2 – 12) 0.638
Total direct non-medical costs 232 (110) 218 (110; 191–253) 290 (150; 224–315) 0.090
Indirect non-medical costs
Agency for child welfare 10 6 (0; 3 – 9) 20 (0; 9 – 20) <0.001
Police 0 0 (0; 0 – 0) 1 (0; 0 – 1) 0.154
Special Education 30 (28) 28 (0; 23 – 33) 36 (0; 28 – 45) 0.090
Total indirect non-medical costs 41 34 (0; 28 – 40) 57 (0; 46–68) <0.001
Total costs children 658 (322) 578 (266; 465–691) 839 (511; 648–1029) 0.021
Parents
Direct Medical costs
Doctor’s consultations*,** 60 47 (0; 39 – 57) 88 (33; 69–108) <0.001
Trainings 93 81 (0; 54 – 109) 118 (0; 74 – 166) 0.145
Medication 1.60 0.93 (0; 0.5 – 1.3) 3.1 (0; 2 – 4) <0.001
Total direct medical costs 154 130 (0; 98 – 162) 211 (82; 153–269) 0.010
Indirect non-medical costs
Productivity losses due to absenteeism and presenteeism 136 116 (0; 74 – 159) 181 (0; 113 – 259) 0.092
Total costs parents 292 (65) 246 (21; 191–300) 399 (182; 298–482) 0.006
Children and parents together
Total costs 948 (524) 824 (412; 690–957) 1228 (740; 1003–1453) 0.002
*p value reflects differences between responders and non-responders
**All consultations are summed up. Table 2 provides an overview specified per type of doctor
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comorbidities. This is consistent with the estimation that
in general around 60–100 % of patients with ADHD ex-
hibit one or more comorbid disorders (Faber et al. 2010;
Gillberg et al. 2004). The percentage of 10 % of children
with comorbid ODD/CD and 25 % of ASD in our
study group seems to be low compared to other stud-
ies (Gillberg et al. 2004; Erskine et al. 2014). Anxiety
disorder and mood disorder differed significantly be-
tween the responder and non-responder group with more
cases in the responder group. This outcome was not ex-
pected, since comorbidity is expected to negatively influ-
ence ADHD outcomes (Gillberg et al. 2004).
Recently, a systematic review was performed on European
studies of ADHD-related costs published between 1990
and 2013 (Le et al. 2013). Only seven studies were found.
The studies were conducted in Belgium, the Netherlands,
Germany (n = 3), Sweden and the United Kingdom. All
studies included direct medical costs for children, but only
one study included direct medical costs for family mem-
bers whereas only two included costs of productivity
loss of family members (indirect non-medical costs)
(Hakkaart-van Roijen et al. 2007; Myren et al. 2010).
Considering the methodology and the country of origin,
only one study in the review can be compared well to the
study at hand (Hakkaart-van Roijen et al. 2007). In that
study, three groups were studied based on proxy reporting
by the mother: 70 children treated by a pediatrician for
ADHD, a non-matched group of 35 children with behav-
ior problems and 60 children without behavior problems.
The study showed the yearly direct medical costs of
ADHD patients to be €2040. Moreover, ADHD children
incurred yearly direct medical costs of €5908 which is
in the range we found in our study (€3864 for responders
to €6144 for non-responders). Indirect costs for the
mothers of children with ADHD were €2243 for mothers
compared to €1560 in our responder group and €2172 in
our non-responder group.
It has been described before that studying ADHD is a
challenge and concessions must be made considering time,
money and information needed (Arnold et al. 1997). Limi-
tations of our study are the following. First of all, a practical
choice had to be made regarding selection of participants.
As an alternative, the possibility to include parents of
children already participating in a trial related to ADHD
was discussed. It was decided not to do so, because of bur-
den for participants and potential bias. We chose for par-
ents who are a member of an ADHD parent association.
Because of this membership, it was assumed valid to rely
on the parents’ knowledge about the ADHD diagnosis of
their child. Due to anonymity it was not possible to verify
whether the diagnosis was valid or to collect data on dis-
ease severity. Similar considerations were stated in an earl-
ier study, which used the same method of parent selection
based on considerations of practicability, convenience and
reliability (De Ridder & De Graeve 2006). With respect
to generalizability of this data, future studies should
take the specific study group in this study into account.
Second, other than the descriptions provided by parents,
no insight in actual medication use by means of for ex-
ample a saliva test was available. This has been shown
to provide different results compared to parent report
(Pappadopulos et al. 2009). Third, the definition of non-
responder in this study differs from clinical trials. These
trials mainly aim at short-term effects and therefore at
symptomatic improvement. This study aimed to focus on
functional improvement as well. We explicitly broadened
our definition of response and non-response, given our at-
tempt to add to data generation on burden of illness in
ADHD. Furthermore, it is questioned if current clinical
trial designs in ADHD and response definitions are useful
for measurement of individual treatment response anyway
(Hodgkins et al. 2013). The definition we used provided a
hands-on description of the study groups which provided
easy reference to the respondents. Since we also wanted to
ask questions on quality of life and costs for both the
children and the parents we decided not to increase the
questionnaire any further with a more in-depth descrip-
tion of functioning consisting of multiple questions. The
statement of responders has been carefully assessed by the
experts, but not by parents. We assumed the definition to
be clear to parents, although the potential for alternative
interpretations cannot be fully ruled out. Fourth, since we
relied on a membership pool of an ADHD parent associ-
ation, it could be the case that more severe ADHD cases
were included in this study with a potential upward bias
in the estimation of costs. Although, this is in conflict with
the low percentage of comorbid ODD and ASD. Fifth, due
to the cross-sectional methodology we cannot speculate
about the causal relationship between these results and/or
potential long-term benefits or disadvantages. A sixth
point of interest in this study is that the definition of
‘response to treatment’ and ‘non-response to treatment’
includes some statement on impaired functioning of the
non-responding child. One might postulate that impaired
functioning a priori leads to higher costs. On the other
hand, the response definitions did not include any state-
ment on health care resource use which is the main focus
of this study. Considering the remarkable difference in
costs between both groups, the main conclusion of our
study implying that non-response to treatment leads to
higher costs seems to hold. We therefore assume the
influence of this response definition to be modest only.
Seventh, in case parents reported to have more than one
child with ADHD, they were asked to report on their youn-
gest child in order to reach consistency. The influence of
this guidance is unknown. It could have resulted in under-
estimation of costs due to experience of the parent with
the older child with ADHD, but also in overestimation
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since the youngest child was diagnosed most recently
which could be associated with higher costs or younger
children requiring more attention in general. Finally,
next to pharmacological treatment, other types of treat-
ment could have had an influence on the results since
multimodal interventions are recommended for ADHD
treatment (Daley et al. 2014; Trimbos-instituut et al.
2005). Pharmacological treatment together with interven-
tions using behavioral techniques form the foundation for
ADHD treatment (Trimbos-instituut et al. 2005). A meta-
analysis of randomized controlled trials concluded that be-
havioral interventions have positive effects on a range of
outcomes when used with patients with ADHD (Daley
et al. 2014). Due to the method of our study it cannot be
distinguished what the specific influence of either pharma-
cological treatment or behavioral interventions has been.
On the basis of our study, we would recommend future
studies to use a random sample from multiple countries
with possibilities to confirm diagnosis including validated
checks on compliance, including validated questionnaires
reporting on symptomatology (e.g. ADHD-RS-IV ADHD
Rating Scale version 4 (Makransky & Bilenberg 2014)) and
functioning (e.g. CGI-I Clinical Global Impression scale)
(Busner & Targum 2007)), and existence of a control
group using a longitudinal methodology with patient
self-report, and parent and teacher report.
Conclusions
The results of this study provide relevant information
for health care provision and use, since the results stress
the importance of focusing on achieving response to
treatment in children receiving (pharmacological) treatment
for ADHD. Direct medical costs for children - specifically
day-care treatment and trainings - were identified to be
the most disparate with higher costs in the non-responder
group. Direct non-medical costs were also unequal be-
tween groups with the highest difference in coaching at
school. For parents of children with ADHD, doctor’s con-
sultations were higher in the responder group. Treatment
pathways should incorporate a focus on achieving re-
sponse to treatment reflected in recovery both at home
and at school and proper compliance to prescription.
Also family involvement should be a standard part of
the pathway.
The results of this study contribute to the large evi-
dence gap in societal cost calculation related to ADHD
and emphasize the need for a broad perspective when
analyzing problems related to ADHD since non-medical
costs have a large contribution to total ADHD-related
costs. With the trend of cost-effectiveness studies being
used increasingly in guideline development and clinical
decision-making, there is a clear need for comprehensive
cost studies like the study at hand (Marsden & Wonderling
2013). As was described by others, programs to facilitate
collaboration among payers, patients, employers, and edu-
cational institutions may provide opportunities to create
strategies to consider the societal impact of ADHD and
strategies to mitigate its impact (Doshi et al. 2012). This
study may aid in indicating which parts of healthcare
consumption and non-direct and indirect costs such
strategy should primarily be focused on.
Abbreviations
ADHD: Attention deficit hyperactivity disorder; ASD: Autism spectrum disorder;
C: Compliance; CD: Conduct disorder; Ch: Children; F: Functioning; LE: Linear
extrapolation; ODD: Oppositional defiant disorder; P: Parents; RIAGG: Dutch mental
health facility: a combination of 1st and 2nd line care; TiC-P: Questionnaire on
healthcare consumption and productivity losses for patients with psychiatric
disorders; QoL: Quality of life.
Competing interests
LH, CB and SS have no conflicts of interest. AK is a PhD Student at Radboud
University and also an employee of Janssen-Cilag BV, but is not a shareholder
of this company. MA is a former employee of Janssen-Cilag BV (until September
2014) and currently works for Gilead Sciences BV. JB has been in the past
years a consultant to - member of advisory board of – and/or speaker for
Janssen-Cilag, Eli Lilly, Bristol-Myers Squibb, Schering Plough, UCB, Shire,
Novartis and Servier. He is not an employee of any of these companies,
nor a stock shareholder. He has no other financial or material support,
including expert testimony, patents, and royalties.
Authors’ contributions
AK and MA came up with the idea of the study and have made substantial
contributions to conception and design, acquisition of data, and analysis and
interpretation of data. JB, LH and CB provided their input on the design of
the questionnaire for this specific study. CB was involved in coordination of
the study as she was the contact for parents that had any questions. AK and
MA coordinated the roll out of the study and arranged the set-up of the
online questionnaire and applied necessary policies for privacy of participants.
AK and MA performed the statistical analysis and prepared the first draft of the
manuscript. JB, LH, CB and SS revised the manuscript critically for important
intellectual content. LH, CB and SS supervised the study from a health
technology assessment point of view, whereas JB supervised the study from a
psychiatry point of view. All authors were involved in the interpretation of the
data, and in review and approval of the manuscript. All authors read the final
manuscript and have given approval of this version to be published.
Acknowledgements
We would like to thank Kathleen Provinciael and Baudowine Flipse working for
Janssen-Cilag BV for their support in cooperating with Balans and acquisition of
data by programming the questionnaire. The study was directly funded by
Janssen-Cilag BV, Tilburg, the Netherlands since AK is an employee of this
company and follows a PhD training in order to increase skills for her job. This
funding relates to costs for data collection, publishing and time invested from
AK and MA.
Author details
1Radboud University Medical Centre, Donders Institute for Brain, Cognition
and Behavior, Department of Cognitive Neuroscience, P.O. Box 9010, 6500,
GL, Nijmegen, the Netherlands. 2Janssen-Cilag BV, P.O. Box 90240, 5000, LT,
Tilburg, the Netherlands. 3Institute for Medical Technology Assessment
(iMTA), P.O. Box 1738, 3000, DR, Rotterdam, the Netherlands. 4Karakter Child
and Adolescent Psychiatry University Centre, Reinier Postlaan 12, 6525, GC,
Nijmegen, the Netherlands. 5Gilead Sciences B.V., Amsterdam, The
Netherlands.
Received: 11 February 2015 Accepted: 13 April 2015
References
Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L,
Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Pelham WE,
Richters JE, Schiller E, Severe JB, Swanson JM, Vereen D, Wells KC (1997) National
van der Kolk et al. SpringerPlus  (2015) 4:224 Page 10 of 12
institute of mental health collaborative multimodal treatment study of children
with ADHD (the MTA): Design challenges and choices. Arch Gen Psychiatry
54:865–870
Asherson P (2004) Attention-deficit hyperactivity disorder in the post-genomic era.
Eur Child Adolesc Psychiatry 13(Suppl 1):I50–I70
Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J,
Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J,
Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications
for the hyperkinetic disorders. A systematic review and European treatment
guideline. Eur Child Adolesc Psychiatry 15:476–495
Barkley RA (2008) Global issues related to the impact of untreated attention-deficit/
hyperactivity disorder from childhood to young adulthood. Postgrad Med
120:48–59
Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR
(2005) Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess
costs of persons with ADHD and their family members in 2000. Curr Med Res
Opin 21:195–206
Bouwmans CAM, Hakkaart-van Roijen L (2013a) Questionnaires for the measurement
of costs in economic evaluations. TiC-P, Manual
Bouwmans CAM, Hakkaart-van Roijen L (2013b) TiC-P volwassenen. Vragenlijst
over zorggebruik en productiviteitsverliezen bij psychische aandoeningen.
Bouwmans C, De Jong K, Timman R, Zijlstra-Vlasveld M, Feltz-Cornelis C, Tan SS,
Hakkaart-van Roijen L (2013a) Feasibility, reliability and validity of a questionnaire
on healthcare consumption and productivity loss in patients with a psychiatric
disorder (TiC-P). BMC Health Serv Res 13:217
Bouwmans CAM, Schawo S, Hakkaart-van Roijen L (2013b) TiC-P voor kinderen.
Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M (1995) Prediction of
clinical response to methylphenidate in children with attention-deficit
hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34:1025–1032
Busner J, Targum SD (2007) The clinical global impressions scale: applying a
research tool in clinical practice. Psychiatry (Edgmont) 4:28–37
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (2010)
Canadian ADHD Practice Guidelines third version
Charach A, Fernandez R (2013) Enhancing ADHD medication adherence:
challenges and opportunities. Curr Psychiatry Rep 15:371
Coghill D, Soutullo C, d’Aubuisson C, Preuss U, Lindback T, Silverberg M, Buitelaar J
(2008) Impact of attention-deficit/hyperactivity disorder on the patient and
family: results from a European survey. Child AdolescPsychiatr Ment Health 2:31
College voor zorgverzekeringen afdeling pakket (2006) Richtlijnen voor farmaco-
economisch onderzoek, geactualiseerde versie
Daley D, Van der Oord S, Ferrin M, Danckaerts M, Doepfner M, Cortese S,
Sonuga-Barke EJ (2014) Behavioral interventions in attention-deficit/hyperactivity
disorder: a meta-analysis of randomized controlled trials across multiple outcome
domains. J Am Acad Child Adolesc Psychiatry 53:835–847
Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C,
Santosh P, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Zuddas A,
Coghill D (2009) The quality of life of children with attention deficit/hyperactivity
disorder: a systematic review. Psychiatry, Eur Child Adolesc
Dekker S (2015) Zevende voortgangsrapportage passend onderwijs over de
combinatie van onderwijs en zorg. Brief aan Tweede Kamer op 12 juni 2015.
Referentie 770507
De Ridder A, De Graeve D (2006) Healthcare use, social burden and costs of children
with and without ADHD in Flanders, Belgium. Clin Drug Investig 26:75–90
Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH,
Neumann PJ (2012) Economic impact of childhood and adult attention-
deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc
Psychiatry 51:990–1002
Erskine HE, Ferrari AJ, Polanczyk GV, Moffitt TE, Murray CJ, Vos T, Whiteford HA,
Scott JG (2014) The global burden of conduct disorder and attention-deficit/
hyperactivity disorder in 2010. J Child Psychol Psychiatry
Evans C, Crawford B (2000) Expert judgement in pharmacoeconomic studies.
Guidance and future use Pharmacoeconomics 17:545–553
Faber A, Kalverdijk LJ, den Berg LT d J-v, Hugtenburg JG, Minderaa RB, Tobi H
(2010) Co-morbidity and patterns of care in stimulant-treated children with
ADHD in the Netherlands. Eur Child Adolesc Psychiatry 19:159–166
Faraone SV, Biederman J, Mick E (2006) The age-dependent decline of attention
deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol
Med 36:159–165
Gillberg C, Gillberg IC, Rasmussen P, Kadesjo B, Soderstrom H, Rastam M, Johnson M,
Rothenberger A, Niklasson L (2004) Co-existing disorders in ADHD - implications
for diagnosis and intervention. Eur Child Adolesc Psychiatry 13(Suppl 1):I80–I92
Hakkaart-van Roijen L, Zwirs BW, Bouwmans C, Tan SS, Schulpen TW, Vlasveld L,
Buitelaar JK (2007) Societal costs and quality of life of children suffering from
attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry
16:316–326
Hakkaart-van Roijen L, Tan SS, Bouwmans CAM (2011) Handleiding voor
kostenonderzoek. Methoden en standaard kostprijzen voor economische
evaluaties in de gezondheidszorg. Geactualiseerde versie 2010. In: Diemen
(ed) College voor zorgverzekeringen (CVZ)
Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of
integrating medication adherence into pharmacoeconomic analyses: the
example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12:159–166
Hodgkins P, Dittmann RW, Sorooshian S, Banaschewski T (2013) Individual
treatment response in attention-deficit/hyperactivity disorder: broadening
perspectives and improving assessments. Expert Rev Neurother 13:425–433
Jonsson B (2009) Ten arguments for a societal perspective in the economic
evaluation of medical innovations. Eur J Health Econ 10:357–359
Kengetallen SF (2012) Prognose geneesmiddelkosten over 10 jaar. Pharm Weekbl
147:1–2
Landelijke beroepsvereniging remedial teachers (2014) Tarieven remidial teaching.,
http://www.lbrt.nl/
Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J, Erder MH, Doshi JA
(2013) Economic impact of childhood/adolescent ADHD in a European
setting: the Netherlands as a reference case. Psychiatry, Eur Child Adolesc
Makransky G, Bilenberg N (2014) Psychometric properties of the parent and
teacher ADHD Rating Scale (ADHD-RS): measurement invariance across
gender, age, and informant. Assessment 21:694–705
Manca A, Palmer S (2005) Handling missing data in patient-level cost-effectiveness
analysis alongside randomised clinical trials. Appl Health Econ Health Policy
4:65–75
Mannuzza S, Klein RG, Moulton JL III (2008) Lifetime criminality among boys with
attention deficit hyperactivity disorder: a prospective follow-up study into
adulthood using official arrest records. Psychiatry Res 160:237–246
Marsden G, Wonderling D (2013) Cost-effectiveness analysis: role and implications.
Phlebology 28(Suppl 1):135–140
Michielsen M, Semeijn E, Comijs HC, van de Ven P, Beekman AT, Deeg DJ, Kooij JJ
(2012) Prevalence of attention-deficit hyperactivity disorder in older adults in
The Netherlands. Br J Psychiatry 201:298–305
Myren KJ, Thernlund G, Nylen A, Schacht A, Svanborg P (2010) Atomoxetine’s
effect on societal costs in Sweden. J Atten Disord 13:618–628
Osterhaus JT, Gutterman DL, Plachetka JR (1992) Healthcare resource and lost
labour costs of migraine headache in the US. Pharmacoeconomics 2:67–76
Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL,
Hechtman L, Chuang S, Wells KC, Pelham W, Cooper T, Elliott G, Newcorn JH
(2009) Medication adherence in the MTA: saliva methylphenidate samples
versus parent report and mediating effect of concomitant behavioral
treatment. J Am Acad Child Adolesc Psychiatry 48:501–510
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide
prevalence of ADHD: a systematic review and metaregression analysis. Am J
Psychiatry 164:942–948
Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE (2012) A
systematic review and analysis of long-term outcomes in attention deficit
hyperactivity disorder: effects of treatment and non-treatment. BMC Med
10:99
Swanson JM, Wigal T, Lakes K (2009) DSM-V and the future diagnosis of
attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 11:399–406
Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A
(2003) Attention-deficit/hyperactivity disorder: increased costs for patients
and their families. J Am Acad Child Adolesc Psychiatry 42:1415–1423
Thompson AL, Molina BS, Pelham W Jr, Gnagy EM (2007) Risky driving in
adolescents and young adults with childhood ADHD. J Pediatr Psychol
32:745–759
Trimbos-instituut, Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in
de ggz, Werkgroep ADHD bij kinderen en jeugdigen (2005) Multidisciplinaire
Richtlijn ADHD. Richtlijn voor de diagnostiek en behandeling van. ADHD bij
kinderen en jeugdigen, Utrecht
van den Ban E, Souverein P, Meijer W, van Engeland H, Swaab H, Egberts T,
Heerdink E (2014) Association between ADHD drug use and injuries among
children and adolescents. Eur Child Adolesc Psychiatry 23:95–102
van Onderwijs CWM (2012) Kerncijfers 2007–2011. Onderwijs, Cultuur en Wetenschap
National Institute for Health and Clinical Excellence (2006) Methylphenidate,
atomoxetine and dexamfetamine for attention deficit hyperactivity disorder
van der Kolk et al. SpringerPlus  (2015) 4:224 Page 11 of 12
(ADHD) in children and adolescents. NICE, London, 2006 Mar [online].
http://www.nice.org.uk/TA098
Nederlandse Orde van Alternatieve Genezers (2013) Unit cost for alternative
therapist., www.noag.org
Nibud (2013) Hoeveel betaalt u de oppas?., http://www.nibud.nl/uitgaven/
kinderen/oppas.html
van den Ban E, Souverein P, Swaab H, van EH, Heerdink R, Egberts T (2010)
Trends in incidence and characteristics of children, adolescents, and adults
initiating immediate-or extended-release methylphenidate or atomoxetine in
the Netherlands during 2001–2006. J Child Adolesc Psychopharmacol 20:55–61
van der Kolk A, Bouwmans CAM, Schawo SJ, Buitelaar JK, van Agthoven M,
Hakkaart-van Roijen L (2014) Association between quality of life and treatment
response in children with attention deficit hyperactivity disorder and their
parents. J Ment Health Policy Econ 17:111–121
van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF (1996) Labor
and health status in economic evaluation of health care. The Health and
Labor Questionnaire. Int J Technol Assess Health Care 12:405–415
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG,
Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S (2011)
ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment
of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics
128:1007–1022
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
van der Kolk et al. SpringerPlus  (2015) 4:224 Page 12 of 12
